Catalent, Inc. (NYSE:CTLT) Shares Bought by ING Groep NV

ING Groep NV boosted its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 4.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 502,580 shares of the company's stock after buying an additional 22,448 shares during the quarter. ING Groep NV owned approximately 0.28% of Catalent worth $22,581,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CTLT. Panagora Asset Management Inc. raised its position in Catalent by 78.9% in the fourth quarter. Panagora Asset Management Inc. now owns 21,766 shares of the company's stock valued at $978,000 after purchasing an additional 9,600 shares during the period. Inceptionr LLC purchased a new position in Catalent in the fourth quarter valued at approximately $224,000. Dimensional Fund Advisors LP raised its holdings in Catalent by 29.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company's stock worth $73,655,000 after purchasing an additional 376,931 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Catalent during the 4th quarter worth approximately $348,000. Finally, Thompson Siegel & Walmsley LLC boosted its holdings in shares of Catalent by 31.2% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 924,305 shares of the company's stock valued at $41,530,000 after buying an additional 219,983 shares in the last quarter.

Catalent Stock Performance

CTLT stock traded up $0.12 during mid-day trading on Friday, hitting $55.37. 1,079,423 shares of the company were exchanged, compared to its average volume of 1,682,707. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The stock has a market capitalization of $10.02 billion, a PE ratio of -9.08, a price-to-earnings-growth ratio of 6.67 and a beta of 1.18. The business has a 50 day simple moving average of $56.19 and a 200-day simple moving average of $50.10. Catalent, Inc. has a 1-year low of $31.50 and a 1-year high of $60.20.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. On average, equities analysts forecast that Catalent, Inc. will post 0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CTLT has been the subject of a number of recent analyst reports. Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. UBS Group restated a "neutral" rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Barclays lifted their price objective on Catalent from $45.00 to $47.00 and gave the stock an "equal weight" rating in a report on Thursday, January 25th. Stephens reiterated an "equal weight" rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Finally, StockNews.com started coverage on shares of Catalent in a research note on Monday, May 13th. They set a "sell" rating on the stock. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.